The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Allogeneic transplantation in FLT3-mutated AML: current role and future directions
Robert Negrin, MD, Stanford University, Stanford, CA, discusses the role of allogeneic stem cell transplantation in patients with FLT3-mutated acute myeloid leukemia (AML) achieving first remission. He explains why transplant remains the preferred approach for most eligible patients despite advances in targeted therapies, while also outlining the clinical and logistical factors that may influence decision-making, including age, comorbidities, donor availability, and transplant feasibility. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
